• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    40 Stocks Moving In Wednesday's Mid-Day Session

    4/6/22 1:19:51 PM ET
    $ADN
    $AEI
    $AIHS
    $ANGH
    Industrial Machinery/Components
    Miscellaneous
    Real Estate
    Finance
    Get the next $ADN alert in real time by email

    Gainers

    • Advent Technologies Holdings, Inc. (NASDAQ:ADN) shares jumped 77.7% to $3.5950. Advent Technologies and Hyundai Motor Company entered into technology assessment, sales and development agreement.
    • Tufin Software Technologies Ltd. (NYSE:TUFN) gained 43% to $12.91 after the company announced it will be acquired by Turn/River Capital for $13 per share in cash.
    • Missfresh Limited (NASDAQ:MF) climbed 27% to $1.6250.
    • Sunshine Biopharma, Inc. (NASDAQ:SBFM) gained 26% to $7.10. Sunshine Biopharma announced that two of its newly designed mRNA molecules are effective at destroying cancer cells grown in culture.
    • Nuvectis Pharma, Inc. (NASDAQ:NVCT) jumped 23.5% to $10.65.
    • NextDecade Corporation (NASDAQ:NEXT) shares climbed 15.3% to $6.89. NextDecade and ENN executed 1.5 MTPA LNG sale and purchase agreement.
    • Team, Inc. (NYSE:TISI) gained 15.3% to $2.5702. Team recently regained compliance with NYSE listing standards.
    • Alset EHome International Inc. (NASDAQ:AEI) rose 14.6% to $0.6313. Alset EHome International recently reported FY2021 results with a 22% revenue growth.
    • Smart Sand, Inc. (NASDAQ:SND) gained 13.4% to $4.15.
    • BioXcel Therapeutics, Inc. (NASDAQ:BTAI) gained 13.3% to $22.52 after the company announced FDA approval of IGALMI sublingual film for acute treatment of agitation associated with Schizophrenia or bipolar I or II disorder in adults.
    • Fresh Vine Wine, Inc. (NYSE:VINE) gained 11.6% to $4.14. Fresh Vine Wine named Ellen Scipta as CFO.
    • BigBear.ai Holdings, Inc. (NYSE:BBAI) rose 8.6% to $11.23 after jumping around 18% on Tuesday.
    • Gogo Inc. (NASDAQ:GOGO) shares rose 8.1% to $20.75. Gogo recently named Sergio Aguirre as President and COO.
    • Sunshine Biopharma, Inc. (NASDAQ:SBFM) shares rose 18.1% to $6.62. Sunshine Biopharma shares jumped 148% on Tuesday after the company announced that two of its designed mRNA molecules are effective at destroying cancer cells grown in culture.
    • Guardion Health Sciences, Inc. (NASDAQ:GHSI) rose 7.4% to $0.2275. Guardion Health Sciences recently reported FY21 loss of $1.04 per share.


    Don’t forget to check out our premarket coverage here .

    Losers

    • Guardforce AI Co., Limited (NASDAQ:GFAI) dropped 32% to $1.14 as the company reported pricing of $10.0 million registered direct offering.
    • Senmiao Technology Limited (NASDAQ:AIHS) shares dipped 26.6% to $1.58. Senmiao Technology reported a 1-for-10 reverse stock split, effective Apr. 6, 2022.
    • Velo3D, Inc. (NYSE:VLD) fell 22.8% to $6.64.
    • Sensus Healthcare, Inc. (NASDAQ:SRTS) dropped 21.9% to $8.60.
    • Hyzon Motors Inc. (NASDAQ:HYZN) fell 18.7% to $5.05 after Canaccord Genuity downgraded the stock from Buy to Hold and lowered its price target from $12 to $6.
    • Swvl Holdings Corp. (NASDAQ:SWVL) dropped 18.6% to $7.04.
    • Nutex Health Inc. (NASDAQ:NUTX) fell 17.7% to $21.92.
    • Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) dipped 17.6% to $9.65. Rhythm Pharmaceuticals will modify its Phase 3 EMANATE and ongoing Phase 2 DAYBREAK trials of setmelanotide in rare genetic diseases of obesity.
    • Celsion Corporation (NASDAQ:CLSN) dropped 17.5% to $5.13 after the company announced a $7 million registered direct offering priced at-the-market under Nasdaq rules.
    • Beam Global (NASDAQ:BEEM) dipped 17.2% to $21.01.
    • Anghami Inc. (NASDAQ:ANGH) fell 16.7% to $11.18 after jumping around 48% on Tuesday.
    • Greenidge Generation Holdings Inc. (NASDAQ:GREE) dropped 16.6% to $8.96.
    • Nextdoor Holdings, Inc. (NASDAQ:KIND) dipped 15.7% to $5.42.
    • Avis Budget Group, Inc. (NASDAQ:CAR) dropped 13.9% to $238.13 after B of A Securities downgraded the stock from Neutral to Underperform and lowered its price target from $250 to $240.
    • Aterian, Inc. (NASDAQ:ATER) shares fell 13.6% to $3.1550. Aterian recently said that Cynthia Williams has joined the Company's Board of Directors.
    • Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) dropped 13.5% to $2.1010.
    • Cano Health, Inc. (NYSE:CANO) dipped 13.1% to $5.47 after Piper Sandler downgraded the stock from Neutral to Underweight and lowered its price target from $8.50 to $5.
    • ChargePoint Holdings, Inc. (NYSE:CHPT) dropped 11.8% to $17.19.
    • Sphere 3D Corp. (NYSE:ANY) dipped 11% to $2.25.
    • Owlet, Inc. (NYSE:OWLT) fell 10.8% to $4.15.
    • Homology Medicines, Inc. (NASDAQ:FIXX) dropped 10.7% to $2.57. Canaccord Genuity maintained Homology Medicines (NASDAQ:FIXX) with a Buy and lowers the price target from $19 to $7.
    • Tantech Holdings Ltd (NASDAQ:TANH) fell 9.7% to $0.6010 after surging around 31% on Tuesday. Tantech recently said its subsidiary, Shangchi Automobile Co Ltd, won an additional ten vehicle orders.
    • Redbox Entertainment Inc. (NASDAQ:RDBX) fell 8.6% to $2.0099.
    • TD Holdings, Inc. (NASDAQ:GLG) fell 7.5% to $0.2930. GLG Life Tech recently reported Q4 results.
    • Inventiva S.A. (NASDAQ:IVA) fell 6% to $11.28. The FDA completed a safety review of Inventiva’s IND application and signed off Phase 2 combination trial with its lead drug candidate, lanifibranor.
    Get the next $ADN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADN
    $AEI
    $AIHS
    $ANGH

    CompanyDatePrice TargetRatingAnalyst
    NextDecade Corporation
    $NEXT
    2/6/2026$7.00Overweight
    CapitalOne
    Inventiva S.A.
    $IVA
    1/28/2026$18.00Overweight
    Barclays
    Inventiva S.A.
    $IVA
    1/12/2026$12.00Outperform
    Leerink Partners
    BigBear.ai Inc.
    $BBAI
    1/7/2026$6.00Overweight → Neutral
    Cantor Fitzgerald
    Inventiva S.A.
    $IVA
    1/7/2026$12.00Buy
    UBS
    Gogo Inc.
    $GOGO
    12/9/2025Outperform → Mkt Perform
    William Blair
    Owlet Inc.
    $OWLT
    12/9/2025Outperform
    William Blair
    Rhythm Pharmaceuticals Inc.
    $RYTM
    11/25/2025$136.00Buy
    Citigroup
    More analyst ratings

    $ADN
    $AEI
    $AIHS
    $ANGH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chair Thorne Oakleigh bought $907,300 worth of shares (170,000 units at $5.34), increasing direct ownership by 22% to 954,098 units (SEC Form 4)

    4 - Gogo Inc. (0001537054) (Issuer)

    12/16/25 4:44:04 PM ET
    $GOGO
    Telecommunications Equipment
    Consumer Discretionary

    Large owner Hanwha Aerospace Co., Ltd. bought $9,399,378 worth of shares (1,651,971 units at $5.69) (SEC Form 4)

    4 - NextDecade Corp (0001612720) (Issuer)

    12/15/25 7:12:58 PM ET
    $NEXT
    Oil & Gas Production
    Utilities

    Large owner Hanwha Aerospace Co., Ltd. bought $5,742,414 worth of shares (932,598 units at $6.16) (SEC Form 4)

    4 - NextDecade Corp (0001612720) (Issuer)

    12/10/25 8:15:10 PM ET
    $NEXT
    Oil & Gas Production
    Utilities

    $ADN
    $AEI
    $AIHS
    $ANGH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Saunders Scott J

    4 - Nutex Health, Inc. (0001479681) (Issuer)

    2/9/26 1:04:42 PM ET
    $NUTX
    Real Estate

    SEC Form 4 filed by Director Reed Michael Lee

    4 - Nutex Health, Inc. (0001479681) (Issuer)

    2/9/26 1:01:09 PM ET
    $NUTX
    Real Estate

    SEC Form 4 filed by Director Grenas Cheryl Yvonne

    4 - Nutex Health, Inc. (0001479681) (Issuer)

    2/9/26 12:56:37 PM ET
    $NUTX
    Real Estate

    $ADN
    $AEI
    $AIHS
    $ANGH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Guardforce AI Signs Non-binding Letter of Intent to Acquire Leading AI-Powered Speech Therapy and Development Platform

    NEW YORK, NY, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Guardforce AI Co., Limited ("Guardforce AI" or the "Company") (NASDAQ:GFAI, GFAIW)), an AI-driven technology company providing Agentic AI, smart solutions in automation, robotics, and secured logistics, today announced it has entered into a non-binding Letter of Intent (LOI) to acquire 100% of the issued and outstanding share capital of MGAI Limited ("MGAI"), a pioneer in AI-driven solutions for speech therapy and development management and rehabilitation services. Utilizing advanced AI technology and one of China's largest domestic databases for children's language development assessment, MGAI has built a service ecosystem combining proprie

    2/9/26 8:30:00 AM ET
    $GFAI
    Diversified Commercial Services
    Consumer Discretionary

    Swvl Secures a New Up to $1.5 Million Multi-Year Contract in Saudi Arabia, Expanding Its Healthcare Mobility Footprint Across the GCC

    DUBAI, United Arab Emirates, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Swvl Holdings Corp ("Swvl" or the "Company") (NASDAQ:SWVL), a leading provider of technology-enabled mass mobility solutions, today announced the signing of a new three-year contract valued at up to $1.5 million in the Kingdom of Saudi Arabia ("KSA"), marking a significant expansion of its healthcare mobility operations across the Gulf Cooperation Council ("GCC"). The agreement will support patient, medical staff, and equipment transportation across healthcare facilities, leveraging Swvl's technology platform to enable dynamic route planning, real-time dispatching, and operational optimization. The deployment is designed to su

    2/9/26 7:00:00 AM ET
    $SWVL
    Real Estate

    Sensus Healthcare to Report Fourth Quarter and Full Year 2025 Financial Results and Hold Business Update Conference Call on February 12, 2026

    Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after t

    2/5/26 8:00:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $ADN
    $AEI
    $AIHS
    $ANGH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for IGALMI issued to BIOXCEL THERAPEUTICS, INC.

    Submission status for BIOXCEL THERAPEUTICS, INC.'s drug IGALMI (ORIG-1) with active ingredient DEXMEDETOMIDINE has changed to 'Approval' on 04/05/2022. Application Category: NDA, Application Number: 215390, Application Classification: Type 3 - New Dosage Form

    4/6/22 2:18:32 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADN
    $AEI
    $AIHS
    $ANGH
    SEC Filings

    View All

    SEC Form 8-K filed by Team Inc.

    8-K - TEAM INC (0000318833) (Filer)

    2/9/26 4:15:50 PM ET
    $TISI
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by BioXcel Therapeutics Inc.

    SCHEDULE 13G/A - BioXcel Therapeutics, Inc. (0001720893) (Subject)

    2/9/26 4:13:17 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Swvl Holdings Corp

    6-K - Swvl Holdings Corp (0001875609) (Filer)

    2/9/26 4:09:49 PM ET
    $SWVL
    Real Estate

    $ADN
    $AEI
    $AIHS
    $ANGH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CapitalOne initiated coverage on NextDecade with a new price target

    CapitalOne initiated coverage of NextDecade with a rating of Overweight and set a new price target of $7.00

    2/6/26 8:35:07 AM ET
    $NEXT
    Oil & Gas Production
    Utilities

    Barclays initiated coverage on Inventiva with a new price target

    Barclays initiated coverage of Inventiva with a rating of Overweight and set a new price target of $18.00

    1/28/26 7:17:30 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Inventiva with a new price target

    Leerink Partners initiated coverage of Inventiva with a rating of Outperform and set a new price target of $12.00

    1/12/26 8:13:43 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADN
    $AEI
    $AIHS
    $ANGH
    Leadership Updates

    Live Leadership Updates

    View All

    Team, Inc. Announces Planned Leadership Transition and Names Gary Hill as Chief Executive Officer

    SUGAR LAND, Texas, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Team, Inc. (NYSE:TISI) ("TEAM" or the "Company"), a leading provider of specialty industrial services offering a full suite of mechanical, heat-treating, and inspection services around the world, today announced that Keith Tucker will retire from Team after over 20 years of service. In conjunction with this planned leadership transition, TEAM's Board of Directors has appointed Gary Hill as the Company's Chief Executive Officer effective February 1, 2026 to lead the Company in its continued focus on driving accelerated growth and margin improvements. The Company also reaffirms its previously issued 2025 outlook. "On behalf of the Board o

    1/26/26 5:00:00 PM ET
    $TISI
    Other Consumer Services
    Consumer Discretionary

    BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting

    Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home Setting as Early as Year-End 2026 BioXcel Therapeutics on Track to Submit a sNDA for IGALMI® this Month NEW HAVEN, Conn., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced the advancement of its commercial planning for IGALMI® in the at-home setting. As part of this, Mark Pavao, a commercial planning and launch advisor with more than 3

    1/12/26 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sensus Healthcare Appoints Larry Biscotti to its Board of Directors

    Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Larry Biscotti to its Board of Directors, effective immediately. With this appointment the Sensus Healthcare Board has six Directors, including four independent Directors. Mr. Biscotti brings more than 25 years of executive leadership experience in the medical device and healthcare technology sectors, with an extensive background in driving commercial strategy, expanding global market share and launching advanced imaging and oncology technologi

    1/7/26 8:30:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $ADN
    $AEI
    $AIHS
    $ANGH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by BigBear.ai Inc.

    SC 13D/A - BigBear.ai Holdings, Inc. (0001836981) (Subject)

    12/16/24 9:09:02 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by BigBear.ai Inc.

    SC 13D/A - BigBear.ai Holdings, Inc. (0001836981) (Subject)

    12/12/24 4:17:36 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by BigBear.ai Inc.

    SC 13D/A - BigBear.ai Holdings, Inc. (0001836981) (Subject)

    12/10/24 4:15:32 PM ET
    $BBAI
    Computer Software: Prepackaged Software
    Technology

    $ADN
    $AEI
    $AIHS
    $ANGH
    Financials

    Live finance-specific insights

    View All

    Sensus Healthcare to Report Fourth Quarter and Full Year 2025 Financial Results and Hold Business Update Conference Call on February 12, 2026

    Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after t

    2/5/26 8:00:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Avis Budget Group to Announce Fourth Quarter 2025 Results on February 18th

    PARSIPPANY, N.J., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ:CAR) announced today that it plans to report its fourth quarter 2025 results after the market close on Wednesday, February 18th, 2026, and to host a conference call for institutional investors to discuss these results on Thursday, February 19th, 2026, at 8:30 a.m. Eastern time. Investors may access the call at ir.avisbudgetgroup.com, or by dialing (877)-407-2991. Investors are encouraged to dial in approximately 10 minutes prior to the call. A Web replay will be available at ir.avisbudgetgroup.com following the call. A telephone replay will be available from 12:30 p.m. Eastern time on February 19th, 2026,

    1/15/26 4:00:35 PM ET
    $CAR
    Rental/Leasing Companies
    Consumer Discretionary

    Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome

    -- BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy -- -- Promising results supportive of Phase 3, registrational trial of setmelanotide in PWS -- -- Company initiated Phase 1, Part D study to evaluate weekly MC4R agonist RM-718 in patients with PWS -- -- Company to hold conference call on Thursday, December 11 at 8:00 a.m. -- BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today

    12/11/25 7:30:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care